Novo Nordisk A/S (NVO · NYSE)
NVO · MARKET VIEW
Market view · as of Aug 31, 2026
Revenue (TTM)
$329.43B
+2.1% YoY
Gross margin
82.0%
EPS (latest q)
$0.96
vs $0.82 est · beat
52-wk position
42.1%
-25.3% vs 52w high · -1.9% 1mo
Price (last ~year)
Novo Nordisk (NVO) reported a decline in quarterly revenue to $78.49 billion from $96.82 billion in the previous period, contributing to a 20.6% year-over-year drop in earnings despite 2.1% growth in TTM revenue of $329.43 billion. The company maintains an operating margin of 42.5% and is currently executing a DKK 15 billion share buyback program. Shares are trading at $45.61, compared to an analyst target of $47.08, amid ongoing competitive pressure in the weight-loss drug market.
Valuation
- Market cap
- $201.64B
- P/E
- 11.29
- PEG
- 3.137
- P/B
- 5.92
- P/S
- 0.612
- EV/EBITDA
- 9.47
- Beta
- 0.349
- Analyst target
- $47.08
Quality & returns
- Gross margin
- 82.0%
- Operating margin
- 42.5%
- Profit margin
- 35.3%
- ROE
- 59.8%
- ROA
- 18.7%
Price movement
- Last
- $45.61
- 1-month
- -1.9%
- 3-month
- +10.0%
- RSI (14)
- 43
- vs SMA200
- +1.1%
- 52-wk position
- 42.1% -25.3% vs high
Quarterly trajectory
Revenue by quarter (oldest → newest)
| Quarter | Revenue | Op income | Net income | EBITDA |
|---|---|---|---|---|
| 2026-06-30 | $78.49B | $27.06B | $20.99B | $38.68B |
| 2026-03-31 | $96.82B | $59.62B | $48.56B | $69.21B |
| 2025-12-31 | $79.14B | $31.74B | $26.89B | $39.75B |
| 2025-09-30 | $74.98B | $23.68B | $20.01B | $33.27B |
Recent news
- Neutral Eli Lilly vs Novo Nordisk: One Winner in The Weight-Loss Drug Gold Rush · 2026-08-25
- Somewhat-Bullish Novo Nordisk Details Progress in DKK 15 Billion Share Buyback Programme · 2026-08-24
- Neutral What Pharmacists Should Know About Novo Nordisk–Eli Lilly GLP-1 Ad Suit · 2026-08-24
- Neutral Eli Lilly and Novo Nordisk Can't Treat This Form of Obesity. Billionaire Stanley Druckenmiller Is Betting Rhythm Pharmaceuticals Can · 2026-08-23
- Neutral How cost and perception could reshape the GLP-1 market · 2026-08-21
- Neutral Novo Nordisk commences study for reduced Wegovy pill dosing · 2026-08-20
Sources this view read
- fundamentals Company overview & valuation (Alpha Vantage OVERVIEW)
- filing Quarterly financial statements (Alpha Vantage INCOME/BALANCE/CASH)
- earnings Reported earnings history (Alpha Vantage EARNINGS)
- prices Adjusted daily prices (Alpha Vantage TIME_SERIES_DAILY_ADJUSTED)